NextGen Day

Apparently slowing the advancement of Alzheimer’s disease, a new medicine was approved by the US Food and Drug Administration (FDA) on Friday.

The FDA stated that individuals with mild or early stages of the condition that deteriorates the brain will be prescribed Leqembi, also known chemically as lecanemab.

The medication is the first of its type to persuade scientists that it can delay the deterioration of memory and reasoning.

However, according to specialists, the treatment will only likely delay cognitive decline by a few months, which can be a very long time for families who have loved ones who have Alzheimer’s disease.

This medicine is not a panacea. According to Joy Snider, a neurologist at Washington University in St. Louis, “it measurably slows the trajectory of the disease, but it doesn’t stop patients from becoming worse.” “That might give someone an additional six to twelve months of driving ability.”

According to medical professionals, the medication has risks and drawbacks, including potential side effects like brain enlargement and the requirement for twice-monthly infusions.

Japan’s Eisai and its US partner Biogen produce Leqembi. The drug will cost roughly $26,500 for a typical year of therapy, according to the manufacturer, who claimed that this high price reflects the drug’s advantages, which include increased quality of life and fewer loads for caregivers.

The next obstacle is the difficulty in getting the medication to patients because it may take many months for Leqembi to be disseminated and because the insurance must now choose whether and how to fund the expensive medication’s cost.

The FDA’s approval was based on one mid-stage trial involving 800 individuals who were still capable of living independently or with little help but had early-stage Alzheimer’s disease.

Additionally, Eisai released the findings of a bigger trial involving 1,800 patients, which the FDA will examine to verify the drug’s advantages.

Health professionals estimate that millions of people worldwide also suffer from Alzheimer’s disease, which affects close to six million Americans.

The parts of the brain required for memory thought communication and daily duties are gradually attacked by Alzheimer’s disease.

Save/Share this story with QR CODE

---

Disclaimer

This article is for informational purposes only and does not constitute endorsement of any specific technologies or methodologies and financial advice or endorsement of any specific products or services.

📩 Need to get in touch?

📩 Feel free to Contact NextGenDay.com for comments, suggestions, reviews, or anything else.

---

We appreciate your reading. 😊Simple Ways To Say Thanks & Support Us:
1.) ❤️GIVE A TIP. Send a small donation thru Paypal😊❤️
Your DONATION will be used to fund and maintain NEXTGENDAY.com
Subscribers in the Philippines can make donations to mobile number 0917 906 3081, thru GCash.
3.) 🛒 BUY or SIGN UP to our AFFILIATE PARTNERS.
4.) 👍 Give this news article a THUMBS UP, and Leave a Comment (at Least Five Words).

---

AFFILIATE PARTNERS

World Class Nutritional Supplements - Buy Highest Quality Products, Purest Most Healthy Ingredients, Direct to your Door! Up to 90% OFF.
Join LiveGood Today - A company created to satisfy the world's most demanding leaders and entrepreneurs, with the best compensation plan today.

---